Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients

被引:32
作者
Al-Harthi, L
Voris, J
Patterson, BK
Becker, S
Eron, J
Smith, KY
D'Amico, R
Mildvan, D
Snidow, J
Pobiner, B
Yau, L
Landay, A
机构
[1] Rush Presbyterian St Lukes Med Ctr, Dept Microbiol Immunol, Chicago, IL 60612 USA
[2] Rush Presbyterian St Lukes Med Ctr, Dept Infect Dis, Chicago, IL 60612 USA
[3] Northwestern Univ, Childrens Mem Hosp, Chicago, IL 60611 USA
[4] Pacific Horizon Med Grp, San Francisco, CA USA
[5] Univ N Carolina, Chapel Hill, NC USA
[6] Beth Israel Med Ctr, New York, NY 10003 USA
[7] GlaxoSmithKline, Res Triangle Pk, NC USA
关键词
antiretroviral naive patients; HAART; HIV; immune reconstitution; T-cell receptor excision circules (TRECs); thymic index;
D O I
10.1111/j.1468-1293.2004.00186.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives To examine the extent of immune reconstitution in treatment-naive patients with CD4 T-cell counts < 500 cells/muL following 48 weeks of highly active antiretroviral therapy (HAART). Methods Thirteen antiretroviral naive patients were evaluated longitudinally for 48 weeks on HAART utilizing immune functional and lymphocyte phenotyping assays, including lymphocyte proliferation assay, flow cytometric evaluation of cell surface markers, and delayed type hypersensitivity skin tests. Virologic responses were monitored using commercially available viral load assays and gag/pol mRNA quantification using simultaneous immunophenotyping/UtraSensitive fluorescence in situ hybridization (ViroTect In Cell HIV-1 Detection Kit; Invirion, Frankfort, MI). Thymic function was evaluated for a subset of four patients using real-time polymerase chain reaction (PCR) for T-cell receptor excision circle (TREC) quantification and thymic scans using computerized axial tomography (CT) of the thymus. Results HAART initiation resulted in a significant decline in plasma viremia and percentage of infected peripheral blood cells, and a rise in CD4 T cells from a baseline median of 207 cells/pL to a week-48 median of 617 cells/muL. The rise was predominately in CD4 memory cells. Naive T cells also increased in number, but at a slower rate. Activated (HLA-DR CD38) CD4 and CD8 T cells were elevated at baseline (24 and 62%, respectively) and declined by week 48 (17 and 36%, respectively) but did not reach normal levels. The number of Fas CD4 T cells increased from a baseline median of 169 to 381 cells/muL at week 48. Both soluble interleukin (IL)-2 and tumour necrosis factor (TNF) II receptors declined by week 48. HIV p24 lymphocyte proliferation assay responses were transiently detected in three patients. TREC values increased from a median 6400 copies/mug at baseline to a week-48 median value of 26 697 copies/mug. Conclusion Immune functional reconstitution was not achieved in these HAART naive patients.
引用
收藏
页码:55 / 65
页数:11
相关论文
共 39 条
  • [31] Steffens C. M., 1999, Clinical Immunology Newsletter, V19, P65, DOI 10.1016/S0197-1859(00)89202-X
  • [32] T cell receptor excision circle (TREC) content following maximum HIV suppression is equivalent in HIV-infected and HIV-uninfected individuals
    Steffens, CM
    Smith, KY
    Landay, A
    Shott, S
    Truckenbrod, A
    Russert, M
    Al-Harthi, L
    [J]. AIDS, 2001, 15 (14) : 1757 - 1764
  • [33] Evaluation of thymopoiesis using T cell receptor excision circles (TRECs): Differential correlation between adult and pediatric TRECs and naive phenotypes
    Steffens, CM
    Al-Harthi, L
    Shott, S
    Yogev, R
    Landay, A
    [J]. CLINICAL IMMUNOLOGY, 2000, 97 (02) : 95 - 101
  • [34] Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function
    Teixeira, L
    Valdez, H
    McCune, JM
    Koup, RA
    Badley, AD
    Hellerstein, MK
    Napolitano, LA
    Douek, DC
    Mbisa, G
    Deeks, S
    Harris, JM
    Barbour, JD
    Gross, BH
    Francis, IR
    Halvorsen, R
    Asaad, R
    Lederman, MM
    [J]. AIDS, 2001, 15 (14) : 1749 - 1756
  • [35] Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen
    Valdez, H
    Smith, KY
    Landay, A
    Connick, E
    Kuritzkes, DR
    Kessler, H
    Fox, L
    Spritzler, J
    Roe, J
    Lederman, MB
    Lederman, HM
    Evans, TG
    Heath-Chiozzi, M
    Lederman, MM
    [J]. AIDS, 2000, 14 (01) : 11 - 21
  • [36] Rationale for immune-based therapies for HIV-1 infection
    Valdez, H
    Al-Harthi, L
    Landay, A
    Lederman, MM
    [J]. JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1998, 131 (03): : 197 - 206
  • [37] Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study
    Yamashita, TE
    Phair, JP
    Muñoz, A
    Margolick, JB
    Detels, R
    O'Brien, SJ
    Mellors, JW
    Wolinsky, SM
    Jacobson, LP
    [J]. AIDS, 2001, 15 (06) : 735 - 746
  • [38] Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: Partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia
    Zaunders, JJ
    Cunningham, PH
    Kelleher, AD
    Kaufmann, GR
    Jaramillo, AB
    Wright, R
    Smith, D
    Grey, P
    Vizzard, J
    Carr, A
    Cooper, DA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02) : 320 - 329
  • [39] Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy
    Zhang, LQ
    Lewin, SR
    Markowitz, M
    Lin, HH
    Skulsky, E
    Karanicolas, R
    He, YX
    Jin, X
    Tuttleton, S
    Vesanen, M
    Spiegel, H
    Kost, R
    van Lunzen, J
    Stellbrink, HJ
    Wolinsky, S
    Borkowsky, W
    Palumbo, P
    Kostrikis, LG
    Ho, DD
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (05) : 725 - 732